Attention deficit hyperactivity disorder predominantly inattentive

Supernus Announces Third Quarter 2023 Financial Results

Retrieved on: 
Wednesday, November 8, 2023

Total revenues (GAAP) of $153.9 million in the third quarter of 2023; total revenues excluding Trokendi XR® net product sales (non-GAAP)(2), increased by 24% in the third quarter of 2023, compared to the same period in 2022

Key Points: 
  • Total revenues (GAAP) of $153.9 million in the third quarter of 2023; total revenues excluding Trokendi XR® net product sales (non-GAAP)(2), increased by 24% in the third quarter of 2023, compared to the same period in 2022
    Qelbree® net product sales of $37.1 million in the third quarter of 2023, a 103% increase compared to the third quarter of 2022 and a 20% increase compared to the second quarter of 2023
    GOCOVRI® net product sales of $32.9 million in the third quarter of 2023, an 18% increase compared to the third quarter of 2022 and a 14% increase compared to the second quarter of 2023
    Operating earnings (GAAP) of $8.1 million in the third quarter of 2023, compared to an operating loss (GAAP) of ($1.5) million in the third quarter of 2022
    Adjusted operating earnings (non-GAAP) of $37.3 million in the third quarter of 2023, an increase of 47% compared to the third quarter of 2022
    SPN-830 (apomorphine infusion device) NDA resubmission accepted for review by FDA; PDUFA date of April 5, 2024
    ROCKVILLE, Md., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced financial results for the third quarter of 2023, and associated Company developments.
  • “Our third-quarter performance underscores the strength of our growth products, with combined Qelbree and GOCOVRI net product sales increasing 52% in the third quarter of 2023 compared to the same period last year,” said Jack Khattar, President and CEO of Supernus.
  • Qelbree continues to expand its base of prescribers, with approximately 24,189 prescribers in the third quarter of 2023, up from 21,291 prescribers in the second quarter of 2023.
  • A reconciliation of the full year 2023 financial guidance for Operating Loss (GAAP) to Adjusted Operating Earnings (non-GAAP) is included under the heading “Full Year 2023 Financial Guidance – GAAP to Non-GAAP Adjustments.”
    The Company hosted a successful Research & Development (R&D) Day in October 2023 highlighting clinical and R&D progress and its emerging pipeline of novel CNS product candidates.

Mallinckrodt plc (in Examinership) Reports Third Quarter 2023 Financial Results

Retrieved on: 
Tuesday, November 7, 2023

DUBLIN, Nov. 7, 2023 /PRNewswire/ -- Mallinckrodt plc (in examinership) (OTCMKTS: MNKTQ) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today reported its financial results for the third quarter ended September 29, 2023.

Key Points: 
  • Mallinckrodt's net sales in the third quarter of 2023 were $497.0 million, as compared to $465.4 million in the third quarter of 2022.
  • The Company recorded a net loss for the third quarter of $1,724.8 million, as compared to $284.9 million in the third quarter of 2022.
  • Adjusted gross profit as a percentage of sales was 66.3% for the third quarter of 2023, as compared to 66.2% for the third quarter of 2022.
  • Please see "Non-GAAP Financial Measures" included in this release for a discussion of non-GAAP measures and reconciliation of GAAP and non-GAAP financial measures for the third quarter.

What's your chronotype? Knowing whether you're a night owl or an early bird could help you do better on tests and avoid scams

Retrieved on: 
Tuesday, November 7, 2023

For early risers and late-nighters alike, listening to your internal clock may be the key to success.

Key Points: 
  • For early risers and late-nighters alike, listening to your internal clock may be the key to success.
  • From the classroom to the courtroom and beyond, people perform best on challenging tasks at a time of day that aligns with their circadian rhythm.
  • Some people, known as larks or morning chronotypes, peak early and feel at their best in the morning.

Why your chronotype matters

  • Chronotype can be measured with a simple questionnaire that assesses things like your perceived alertness, preferred rising and retiring times and performance throughout the day.
  • Even without a questionnaire, most people have a sense of whether they are a lark or an owl or fall somewhere in between.
  • People with strong chronotypes are more vigilant and better able to sustain attention at their peak relative to off-peak times.
  • Their memories are sharper, with better list recall and more success in remembering “to-do” tasks like taking medication.
  • For example, a study I conducted gave participants three weakly related cue words (such as “ship,” “outer” and “crawl”).
  • They were tasked to find another word that linked all three (such as “space”).
  • Even ethical behavior can be compromised at non-optimal times, as people are more likely to cheat at their off-peak times.

In the classroom and the clinic

  • This connection is especially significant for teens, who tend to be night owls but typically start school early.
  • One study randomly assigned over 700 adolescents to exam times in the early morning, late morning or afternoon.
  • Time of day may also be a consideration when conducting assessments for cognitive disorders like attention-deficit disorder or Alzheimer’s disease.
  • Simple, easy tasks – like recognizing familiar faces or places, dialing a close friend’s phone number or making a favorite recipe – are unlikely to change over the day.
  • Furthermore, young adults who are neither larks nor owls show less variability in performance over the day.


Cindi May received funding from the National Institute on Aging. She currently serves on the board for Disability Rights South Carolina.

A Senate inquiry says Australia needs a national ADHD framework to improve diagnosis and reduce costs

Retrieved on: 
Tuesday, November 7, 2023

Without appropriate support, ADHD often has lifelong negative impacts on education and employment.

Key Points: 
  • Without appropriate support, ADHD often has lifelong negative impacts on education and employment.
  • The current cost of ADHD to Australia is estimated at more than A$20 billion every year.
  • In response to these concerns, a Greens-chaired Senate inquiry looked at how people access ADHD diagnosis and get support afterwards, the international evidence base, as well as practitioner training and cost.

Not just a mental health issue

  • The committee emphasises that ADHD is not just a mental health issue but a public health concern.
  • The committee members agreed there is a need for a government-funded national framework for ADHD, developed in consultation with people with lived experience.
  • They recommended the NDIS improve the accessibility and quality of information around the eligibility of ADHD as a condition under NDIS.


Read more:
GPs could improve access to ADHD treatment. But we still need specialists to diagnose and start medication

Learning from people with ADHD

  • Trying to navigate pathways to care, even as an expert in ADHD, can be challenging and at times painful in my experience.
  • While public awareness of ADHD has improved greatly in recent years there are still those spreading misinformation and increasing the stigma of people living with ADHD.
  • Read more:
    ADHD medications have doubled in the last decade – but other treatments can help too

A first step

  • The committee recommends
    all levels of government consider investing in the implementation of the Australian ADHD Professionals Association’s Australian evidence-based clinical practice guideline for ADHD.
  • all levels of government consider investing in the implementation of the Australian ADHD Professionals Association’s Australian evidence-based clinical practice guideline for ADHD.
  • Further investment will be needed to ensure the guideline is used properly to promote more holistic care with broader access to key supports.


David Coghill receives funding from the National Health and Medical Research Council and the Medical Research Futures Fund. He is the President of the Australian ADHD Professionals Association and a director of the European ADHD Guidelines Network both not for profit organizations working in the field of ADHD. He has received research funding and/or honoraria from Takeda, Medice, Novartis and Servier.

MindMed Reports Third Quarter 2023 Financial Results and Business Highlights

Retrieved on: 
Thursday, November 2, 2023

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today reported its financial results for the quarter ended September 30, 2023.

Key Points: 
  • Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today reported its financial results for the quarter ended September 30, 2023.
  • Dosing is complete with topline results for the primary endpoint (Week 4) expected to be announced in Q4 2023.
  • R&D expenses were $13.2 million for the quarter ended September 30, 2023, compared to $7.8 million for the quarter ended September 30, 2022, an increase of $5.4 million.
  • MindMed management will host a conference call at 4:30 PM EST today to provide a corporate update and review the Company’s third quarter 2023 financial results.

Otsuka Pharmaceutical Announces Positive Topline Results From Two Pivotal Phase 3 Trials of Centanafadine as a Treatment for Adolescents and Children With Attention-Deficit/Hyperactivity Disorder (ADHD)

Retrieved on: 
Friday, October 27, 2023

Otsuka Pharmaceutical Co., Ltd. and its U.S. subsidiary, Otsuka Pharmaceutical Development & Commercialization, Inc., today announced positive results of two, 6-week, Phase 3 clinical trials that evaluated the efficacy, safety, and tolerability of centanafadine for the treatment of adolescents and children with attention-deficit/hyperactivity disorder (ADHD).

Key Points: 
  • Otsuka Pharmaceutical Co., Ltd. and its U.S. subsidiary, Otsuka Pharmaceutical Development & Commercialization, Inc., today announced positive results of two, 6-week, Phase 3 clinical trials that evaluated the efficacy, safety, and tolerability of centanafadine for the treatment of adolescents and children with attention-deficit/hyperactivity disorder (ADHD).
  • The first trial (NCT05257265) in adolescents aged 13-17 met its primary endpoint by demonstrating improvements from baseline on the ADHD-RS-5 scale.
  • The second trial (NCT05428033) in children aged 6-12 met its primary endpoint by demonstrating improvements from baseline on the ADHD-RS-5 scale.
  • Overall, the safety and tolerability results were consistent with the profile of centanafadine seen within the wider clinical development program.

7-Eleven, Inc.'s 'Brands with Heart' Program Unveils Brands of Tomorrow and Celebrates Those with Purpose

Retrieved on: 
Wednesday, November 1, 2023

IRVING, Texas, Nov. 1, 2023 /PRNewswire/ -- 7-Eleven, Inc., the world's largest convenience retailer, has selected nearly 50 innovative and up-and-coming brands to join the retailer's Brands with Heart™ showcase. The program, now in its fifth year, is designed to give brands the opportunity to enter a new retail channel with the chance to see their products on the shelves across 7-Eleven®, Speedway®, and Stripes® stores in the US.

Key Points: 
  • Following the showcase, select brands will be chosen to participate in an in-store test at participating locations across the U.S.
  • This year, 7-Eleven was proud to discover that all 49 brands selected for the Brands with Heart program exhibit purpose-driven elements within their products and business – supporting people, the planet or the communities they serve.
  • As the Brands with Heart program continues to evolve, there will be a growing focus to recognize standout brands striving to make a positive impact in the world.
  • A list of all brands selected as part of the program is available here.

How do stimulants actually work to reduce ADHD symptoms?

Retrieved on: 
Friday, October 27, 2023

Stimulants are first-line drugs for children and adults diagnosed with attention-deficit hyperactivity disorder (ADHD). But how do they actually work?First, let’s look at the brainMedical imaging indicates people with ADHD may have slight differences in their brain’s structure, the way their brain regions work together to perform tasks, and how their brain’s chemical messengers, called neurotransmitters, pass on information.

Key Points: 


Stimulants are first-line drugs for children and adults diagnosed with attention-deficit hyperactivity disorder (ADHD). But how do they actually work?

First, let’s look at the brain

  • Medical imaging indicates people with ADHD may have slight differences in their brain’s structure, the way their brain regions work together to perform tasks, and how their brain’s chemical messengers, called neurotransmitters, pass on information.
  • These brain differences are associated with the symptoms of ADHD, including inattention, impulse control and problems with memory.

What stimulants are prescribed in Australia?

  • The three main stimulants prescribed for ADHD in Australia are dexamfetamine, methylphenidate (sold under the brand names Ritalin and Concerta) and lisdexamfetamine (sold as Vyvanse).
  • Dexamfetamine and methylphenidate have been around since the 1930s and 1940s respectively.

So how do they work for ADHD?

  • Stimulants increase the amount of dopamine and noradrenaline in the tiny gaps between neurons, known as synapses.
  • They do this by predominantly blocking a transporter that then prevents their re-uptake back into the neuron that released them.
  • Amphetamines also increase the amount of dopamine the neuron releases into the synapse (the tiny gaps between neurons).

What effect do they have on ADHD symptoms?


We still don’t fully understand the underlying brain mechanisms that change behaviour in people with ADHD. But research shows stimulants that modulate noradrenaline and dopamine can improve brain processes such as:
They can also improve general behaviour, such as self-control, not talking over the top of others, and concentration. These behaviours are important for social interactions. Stimulants reduce ADHD symptoms in about 70% to 80% of children and adults who take them. Some people will notice their symptoms improve right away. Other times, these improvements will be more noticeable to parents, carers, teachers, colleagues and partners.

Not everyone gets the same dose


The optimal stimulant dose varies between individuals, with multiple dosage options available. This enables a “start low, go slow” approach, where the stimulant can be gradually increased to the most effective dose for the individual.

  • Dexamfetamine and methylphenidate are available in immediate-release preparations.
  • As these have short half-lives (meaning they act quickly and wear off rapidly), they are often taken multiple times a day – usually in the morning, lunch and afternoon.
  • Methylphenidate is also available in long-acting tablets (Concerta) and capsules (Ritalin LA).

What are the side effects?


The most common side effects are sleep problems and decreased appetite. A recent study showed children and young people taking methylphenidate for ADHD were around 2.6 times more likely to have sleep problems and 15 times more likely to have a decreased appetite than those not taking methylphenidate. Headache and abdominal pain are also relatively common.

Can someone without ADHD take a stimulant to improve productivity?

  • As stimulants increase dopamine, they can cause euphoria and a heightened sense of wellbeing.
  • A common myth about stimulant medicines is they can improve the concentration and productivity of people without ADHD.
  • At each of the sessions, participants were given either a placebo or a stimulant before completing the task.
  • Read more:
    ADHD medications have doubled in the last decade – but other treatments can help too


Mary Bushell does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

REPEAT -- Quoin Pharmaceuticals Announces Additional Positive Clinical Data from Open-Label, Single-Arm Clinical Trial in Netherton Syndrome

Retrieved on: 
Tuesday, October 24, 2023

ASHBURN, Va., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, announces additional positive clinical data from its ongoing open-label study evaluating the safety and efficacy of QRX003 as a potential treatment for Netherton Syndrome (NS).

Key Points: 
  • All subjects in the study are continuing to receive off-label systemic therapy for the duration of the trial.
  • Quoin CEO, Dr. Michael Myers, said, “While acknowledging that this is still early stage data, we are very pleased to announce today additional positive results from our ongoing open-label study in Netherton Syndrome.
  • Furthermore, the absence of any safety concerns from the study to date is a positive indicator for the ongoing clinical development of the product.
  • For more information about Quoin’s clinical trials in Netherton Syndrome, please visit: https://www.nethertonsyndromeclinicaltrials.com/

Quoin Pharmaceuticals Announces Additional Positive Clinical Data from Open-Label, Single-Arm Clinical Trial in Netherton Syndrome

Retrieved on: 
Tuesday, October 24, 2023

ASHBURN, Va., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, announces additional positive clinical data from its ongoing open-label study evaluating the safety and efficacy of QRX003 as a potential treatment for Netherton Syndrome (NS).

Key Points: 
  • ASHBURN, Va., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, announces additional positive clinical data from its ongoing open-label study evaluating the safety and efficacy of QRX003 as a potential treatment for Netherton Syndrome (NS).
  • All subjects in the study are continuing to receive off-label systemic therapy for the duration of the trial.
  • Quoin CEO, Dr. Michael Myers, said, “While acknowledging that this is still early stage data, we are very pleased to announce today additional positive results from our ongoing open-label study in Netherton Syndrome.
  • For more information about Quoin’s clinical trials in Netherton Syndrome, please visit: https://www.nethertonsyndromeclinicaltrials.com/